The Cohera Sylys® Surgical Sealant study is a prospective, randomized, controlled, multicenter technical feasibility clinical study comparing standard anastomosis closure technique (Control) to standard closure techniques plus Sylys® Surgical Sealant (Test) during colorectal and ileorectal anastomosis procedures.
A randomized, double-blind, placebo-controlled, multicenter phase III study to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone-sensitive prostate cancer.
A phase III, randomized, double-blind, placebo-controlled, parallel-group, multicenter, 52-week efficacy and safety study of RO5285119 in adults with Autism Spectrum Disorder (ASD) with a 2-year open-label extension.
A prospective study to understand how trauma injuries change the hematopoietic stem cells (HSCs) in the bone marrow and muscle cells after traumatic injury in elderly subjects is different when compared to non-injured subjects.
This research study is being done to evaluate if the investigational drug, GBR 830, is safe and effective in subjects with moderate to severe atopic dermatitis. This study is also looking at the biological activity of GBR 830 and how it is eliminated from the body. GBR 830 is an investigational drug, which means it is not yet approved by the United States (US) Food and Drug Administration (FDA) or other Health Authorities around the world.
This study will assess the effectiveness of post-cochlear implant or hearing aid fitting Aural Rehabilitative Therapy (ART) delivered by means of telemedicine technology. This will be accomplished primarily by evaluating subjects' language abilities using the 5th Edition of the Preschool Language Scales.
This clinical study evaluates the efficacy and safety of regorafenib in patients with advanced liver cancer who have progressed on sorafenib treatment. Approximately 560 patients who meet the entry criteria will be randomly assigned in a 2:1 ratio to regorafenib or placebo (1/3 chance to receive a placebo). The primary endpoint of the study is overall survival.
The aim is to compare strength, the patient reported outcomes and functional outcomes of postoperative therapy in knee surgery with and without adjunctive BFR training. The investigators will compare differences in quadriceps strength, leg girth, and functional outcome scores between two groups of patients after weeks 6 and 12 as well as 6 months following meniscus or articular cartilage repair/restoration requiring 6 weeks of non-weight bearing or limited weight bearing status in a brace at 0 degrees of knee extension.
This study will be a double-blind, randomized, placebo-controlled, parallel-group study to evaluate the effect of Aclidinium bromide on the cardiovascular safety and COPD exacerbations in patients with moderate to very severe COPD, as defined by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (GOLD, 2011). The objectives of this study are to assess the safety of Aclidinium bromide on major adverse cardiovascular events (MACE), to assess the overall safety of Aclidinium bromide and to assess whether Aclidinium bromide reduces moderate or severe COPD exacerbations.
Researchers are attempting to compare root canal therapy success between two root canal filler materials: 1) gutta percha (GP), 2) gutta percha modified with nanodiamonds and amoxicillin (NDGX).